Bulevirtide plus Tenofovir Disoproxil Fumarate Improves Liver Function in HDV/HBV Related Cirrhosis after Virological Response: A Case Report

Bulevirtide plus Tenofovir Disoproxil Fumarate Improves Liver Function in HDV/HBV Related Cirrhosis after Virological Response: A Case Report

Hepatitis D virus (HDV) globally affects nearly 5% of people with chronic hepatitis B virus (HBV) infection. Bulevirtide (BLV) is an HDV/HBV entry inhibitor recently approved for adult patients with chronic hepatitis delta (CHD). In this real-life case report, we describe the virological efficacy, t...

Full description

Bibliographic Details
Main Authors: Nikolaos Papadopoulos, Panagiotis Tsibouris, Ioannis Braimakis, Periklis Apostolopoulos
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Gastrointestinal Disorders
Subjects:
hepatitis D virus
hepatitis B virus
chronic hepatitis delta
Online Access:https://www.mdpi.com/2624-5647/4/4/26

Internet

https://www.mdpi.com/2624-5647/4/4/26

Similar Items